Comparison · NCT04598477-d46508a2
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Rate of Treatment Failure in Participants With PV and PF
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Rate of Treatment Failure in Participants With PV and PF. Trial comparisons, record NCT04598477-d46508a2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04598477-d46508a2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0297 | 0.0102 | 0.0837 | wilson | |
| Risk in group 2 | 0.0208 | 0.00369 | 0.109 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00887 | -0.0814 | 0.0655 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.43 | 0.152 | 13.4 | log | |
| Odds ratio, group 1 over group 2 | 1.44 | 0.146 | 14.2 | log | |
| Number needed to treat, for one more participant with the outcome on Efgartigimod-efgartigimod PH20 SC than on Placebo-efgartigimod PH20 SC | 113 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Efgartigimod-efgartigimod PH20 SC | Participants who received efgartigimod PH20 SC in antecedent study ARGX-113-1904. | 3 | 101 | OG000 |
| Group 2 | Placebo-efgartigimod PH20 SC | Participants who received placebo PH20 SC in antecedent study ARGX-113-1904. | 1 | 48 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rate of Treatment Failure in Participants With PV and PF
- Description
- The absence of DC with oral prednisone 1.5 mg/kg/day for a minimum of 3 weeks, or absence of DC due to prednisone-related SAE, or flare before CRmin resulting in withdrawal of the participant.
- Time frame
- Up to 52 weeks
- Population
- Safety set
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- NCT number
- NCT04598477
- Phases
- PHASE3
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus
- Interventions
- efgartigimod PH20 SC, prednisone
- Lead sponsor
- argenx
- Results first posted
- 2025-03-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04598477?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04598477-d46508a2